Nav: Home

Doernbecher researchers awarded more than $9 million to fight Fanconi anemia

October 10, 2016

PORTLAND, Ore. - Fanconi anemia is a severe and frequently fatal genetic disease that causes birth defects, bone marrow failure and increased risk of cancer. Despite research advances, medical therapies for the condition have not evolved in more than 30 years.

Thanks to a $9.9 million grant from the National Heart, Lung, and Blood Institute, a team led by Markus Grompe, M.D., director of the Oregon Stem Cell Center at OHSU and the Papé Family Pediatric Research Institute at OHSU Doernbecher Children's Hospital, will work to understand human response to novel drug treatments that have shown promise in FA-positive animal models.

"Three decades is too long to wait for new, targeted therapies - especially when the average life expectancy of an individual living with FA is only 22 years," said Grompe, principal investigator for the study. "We anticipate that the findings of this research will transform the current landscape and may soon yield novel treatments for patients fighting this devastating condition."

In partnership with the laboratories of Alan D'Andrea, M.D. of Harvard University and Akiko Shimamura, M.D., Ph.D., of the Dana Farber Cancer Institute, OHSU will conduct three scientific projects over the course of five years. Two of the projects will prioritize viable drug compounds for clinical study, using animal and human cell models. The results will lead to the third project: a human clinical trial.

"We have already identified several excellent drug candidates; therefore, we fully expect to reach clinical trial phase within our funding period," Grompe explained.

"This important work has the potential to be life-altering for those suffering from FA," said Kevin McQueen, president, Fanconi Anemia Research Fund Board and father of 17-year-old Sean, who was diagnosed with the condition in 2000. "The forthcoming research will lay the groundwork for developing new interventions for FA that could dramatically improve and extend lives. Most importantly, it provides hope of a brighter future for FA families."

This research is supported by The National Heart, Lung, and Blood Institute of the National Institutes of Health (2P01HL048546-21A). Novel therapies for FA are at the very core of the NHLBI mission. This program project represents the only major effort-at the national or international level - in either academia or industry to develop a novel small molecule therapy for this devastating disease.

Oregon Health & Science University

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...